Oncopeptides CEO Jakob Lindberg is “leaning toward” complying with the FDA’s request to formally and completely pull its cancer drug Pepaxto, he told Endpoints News on Thursday, a day after the biotech announced the agency’s ask. But he also accused US regulators of a double standard and claimed it would be unethical to do so, potentially leaving patients in the wind.

In a phone conversation with Endpoints early Thursday afternoon, Lindberg stressed Oncopeptides hasn’t made any decision yet and that one would come within the “next few weeks.” Lindberg and his team are still deliberating whether contesting the FDA’s decision and starting a potentially lengthy legal process would be worth it.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

A couple of the Big 15 biopharma companies in R&D hit the gas on research spending last year. Merck and Sanofi still have lots to prove in the pipeline, and they’re willing to gamble large sums to make a better future for themselves.

Doing nothing would be infinitely worse.

But collectively, the top players rang up a modest 2.4% increase in spending in 2022, which didn’t cover inflationary pressures. And that set the tone for an extraordinarily cautious year for the industry — even as it laid out about $127 billion to advance new drugs or up the ante on approved therapies.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

These days, when Jeffrey Bluestone gets together with his contemporaries in science, the conversation often turns to retirement plans.

But a little more than three years ago, Bluestone reached a momentous turning point in his career, exiting a prestigious post at UCSF, where he had spent decades in the scientific pursuit of new therapies. And it had nothing to do with retirement anytime in the near future.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

From the political arena to the finance and beauty industries to pharmaceuticals, Pfizer’s Sally Susman has broken barriers, stereotypes and conventions. And now the chief communicator is “Breaking Through,” the title of her first book about effective and innovative communications launching today. The full official title is “Breaking Through: Communicating to Open Minds, Move Hearts, and Change the World.”

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN

Over the past year, Simeon George has seen the market chill for biotech, scrambled a crisis team through a harrowing weekend as SVB’s collapse threatened companies in its portfolio and forced them to rework their timeline on support and to rethink his syndicates.

And the CEO is still coming back with a new fund at SR One that is substantially larger than the first they assembled in their breakaway move from the investment arm role they played at GSK.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SIGN UP LOG IN